Exploration of the Immuno-Inflammatory Potential Targets of Xinfeng Capsule in Patients with Ankylosing Spondylitis Based on Data Mining, Network Pharmacology, and Molecular Docking.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
11
2021
accepted:
07
03
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
This study aimed to ascertain the immuno-inflammatory molecular targets of Xinfeng capsules (XFC) in the treatment of ankylosing spondylitis (AS) based on data mining, network pharmacology, and molecular docking. The efficacy of XFC in the treatment of AS was assessed by clinical data mining. Network pharmacology was utilized to establish a network of the targets for XFC active ingredients in the treatment of AS. The binding mode and affinity of XFC active ingredients to the key targets for AS were predicted using molecular docking. XFC significantly diminished immuno-inflammatory indicators of AS. In total, 208 targets of XFC were obtained from the TCMSP database and 629 disease targets of AS were screened from the GeneCards database, which were intersected to yield 57 targets of XFC in the treatment of AS. Protein-protein interaction, gene ontology, and Kyoto genome encyclopedia analyses showed that XFC might activate TNF and NF- Collectively, XFC had a significant therapeutic effect on AS. Specifically, the active ingredients of XFC, including quercetin, kaempferol, triptolide, and formononetin, inhibited the inflammatory response in AS by downregulating TNF and PTGS2 in the TNF and NF-
Identifiants
pubmed: 35368759
doi: 10.1155/2022/5382607
pmc: PMC8967514
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5382607Informations de copyright
Copyright © 2022 Yanyan Fang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Biosystems. 2015 Jan;127:67-72
pubmed: 25451770
Lancet. 2007 Dec 1;370(9602):1861-74
pubmed: 17570481
Pharmaceutics. 2021 Sep 07;13(9):
pubmed: 34575493
Arch Intern Med. 2009 Dec 14;169(22):2094-5
pubmed: 20008692
Yao Xue Xue Bao. 2012 Jun;47(6):696-703
pubmed: 22919715
Cell Death Dis. 2020 Sep 17;11(9):775
pubmed: 32943613
Crit Rev Food Sci Nutr. 2021 May 17;:1-22
pubmed: 33998910
Front Immunol. 2021 Nov 22;12:572592
pubmed: 34880852
J Chem Inf Comput Sci. 2000 Sep-Oct;40(5):1177-87
pubmed: 11045811
J Ethnopharmacol. 2015 Sep 15;173:127-33
pubmed: 26192808
BMC Complement Altern Med. 2019 Aug 2;19(1):198
pubmed: 31375092
PeerJ. 2021 Sep 7;9:e12125
pubmed: 34589304
Exp Ther Med. 2021 May;21(5):529
pubmed: 33815602
Mol Med Rep. 2021 Sep;24(3):
pubmed: 34318900
Cells. 2019 Dec 17;8(12):
pubmed: 31861245
Biomed Res Int. 2021 Sep 20;2021:5507003
pubmed: 34595237
Evid Based Complement Alternat Med. 2020 Jan 24;2020:9719872
pubmed: 32047530
Arch Rheumatol. 2021 Jan 14;36(1):80-88
pubmed: 34046572
Int J Mol Sci. 2012;13(6):6964-82
pubmed: 22837674
Iran J Biotechnol. 2021 Jan 01;19(1):e2630
pubmed: 34179194
J Evid Based Med. 2020 Feb;13(1):57-69
pubmed: 32086994
Evid Based Complement Alternat Med. 2021 Nov 25;2021:8683600
pubmed: 34868333
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Small. 2021 Oct;17(41):e2101505
pubmed: 34499411
Osteoporos Int. 1992 Nov;2(6):285-9
pubmed: 1421796
J Ethnopharmacol. 2013 Apr 19;146(3):773-93
pubmed: 23415946
Biosci Rep. 2020 Jan 31;40(1):
pubmed: 31894846
Evid Based Complement Alternat Med. 2019 Feb 12;2019:7826769
pubmed: 30891080
Arthritis Rheum. 2001 Sep;44(9):2193-200
pubmed: 11592385
Viruses. 2018 Sep 23;10(10):
pubmed: 30249048
Rheumatology (Oxford). 2018 Mar 1;57(3):419-428
pubmed: 28977661